Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants

17 Aug 2021

Abstract excerpt

The successive emergences and accelerating spread of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages and evolved resistance to some ongoing clinical therapeutics increase the risks associated with the coronavirus disease 2019 (COVID-19) pandemic. An urgent intervention for broadly effective therapies to limit the morbidity and mortality of COVID-19 and future transmission events from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34404805
DOI: 10.1038/s41467-021-25331-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variantsPMID 34404805Read ↗

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variantsSemantic proximity Read ↗

ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus BlockerSemantic proximity Read ↗

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blockerSemantic proximity Read ↗

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopesSemantic proximity Read ↗

Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitorsSemantic proximity Read ↗

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variantsSemantic proximity Read ↗

Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockadeSemantic proximity Read ↗

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2Semantic proximity Read ↗

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agentsSemantic proximity Read ↗

Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infectionSemantic proximity Read ↗

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeSemantic proximity Read ↗

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.